News – Page 1098 – Endpoints News

FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche's Avastin

8 years ago

The FDA just unveiled its new, pricier fee schedule to review new drugs

8 years ago

Kerrisdale 2-0 this week: Bavarian Nordic's cancer vaccine is a bust in PhIII

8 years ago

AstraZeneca auctions off more assets in $766M deal, reports positive data for Farxiga

8 years ago

New PhIII data in hand, Pfizer, Astellas hustle ahead in bid to expand US market for Xtandi

8 years ago

Mustang ties the knot with Fred Hutch on next-gen CAR-T for lymphoma

8 years ago

AstraZeneca and Moderna take a big, early step forward in their quest to prove mRNA works in humans

8 years ago

Looking for an I/O edge, Bristol-Myers fronts $105M to partner with Halozyme as Roche expands pact

8 years ago

Great data! Huge potential! (Too bad it failed the primary endpoint)

8 years ago

GSK lines up a shot at a blockbuster market as new CEO prepares to tackle Merck rival head on

8 years ago

Convicted felon Martin Shkreli has finally talked his way behind bars

8 years ago

Martin Shkreli suddenly changes his tune on Clinton threat; Genenta adds $8M for gene therapy R&D

8 years ago

Otonomy brings out the ax after a catastrophic PhIII failure

8 years ago

Mylan attacks Allergan over its Mohawk-allied patent strategy — but the CEO is sticking to his guns

8 years ago

Searching for a few great drugs, BridgeBio bags $135M to back a fresh slate of R&D bets

8 years ago

As rivals look to carve up its blockbuster revenue, Novartis’ Cosentyx registers remarkably consistent effect for ...

8 years ago

Amicus scraps a top rare disease drug after it flunks a pivotal test — and shares spike

8 years ago

Scott Gottlieb is closing a big loophole in the orphan drug law

8 years ago

Gene therapy startup Rocket Pharma reverse merges with troubled Inotek after $25M raise

8 years ago

Another senior AstraZeneca exec jumps ship; Aldeyra shares soar on positive mid-stage data

8 years ago

ProQR spins out a new RNA biotech focused on CNS diseases

8 years ago

Alexion is reorganizing R&D, axing 600-plus jobs and moving HQ to Boston as execs prep deal spree

8 years ago

Sage’s quick flip into PhIII crashes as lead drug fails badly for rare type of seizures

8 years ago

WATCH: Scott Gottlieb vows to shake up the FDA, backing a trend toward faster drug development

8 years ago

First page Previous page 1095 1096 109710981099 1100 1101 Next page Last page